drugset / Trial / NCT01139970
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This phase I clinical trial is studies the side effects and best dose of giving veliparib together with temozolomide in treating patients with acute leukemia. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with temozolomide may kill more cancer cells.
Timeline
- Start
- 2010-06-04
- Primary completion
- 2014-04-15
- Completion
- 2018-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | — | Oral |
| Subject | Veliparib | Small molecule | — | Oral |
Indications
B-cell adult acute lymphocytic leukemia
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
T-cell adult acute lymphocytic leukemia
acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
acute myeloid leukemia, inv(16)(p13.1;q22)
acute myeloid leukemia, t(15;17)(q24;q21)
acute myeloid leukemia, t(16;16)(p13.1;q22)
acute myeloid leukemia, t(8;21)(q22; q22.1)
acute myeloid leukemia, t(9;11)(p21.3;q23.3)
chronic myelomonocytic leukemia